Literature DB >> 6967869

Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

R Reiner, U Weiss, U Brombacher, P Lanz, M Montavon, A Furlenmeier, P Angehrn, P J Probst.   

Abstract

Ro 13-9904/001 is a novel parenteral cephalosporin antibiotic with potent in vitro activity against a wide range of beta-lactamase-producing and non-producing pathogens. In addition, Ro 13-9904/001 proved to possess a very long plasma half-life and, as a consequence, high prophylactic in vivo effectiveness.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6967869     DOI： 10.7164/antibiotics.33.783

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  21 in total

1.  Comparative pharmacokinetics of YM-13115, ceftriaxone, and ceftazidime in rats, dogs, and rhesus monkeys.

Authors:  H Matsui; M Komiya; C Ikeda; A Tachibana
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

2.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

3.  Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

Authors:  P J McNamara; K Stoeckel; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  In vitro susceptibility of Salmonella to various antimicrobial agents, including a new cephalosporin, Ro 13-9904.

Authors:  P Y Chau; W S Ng; J Ling; K Arnold
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

5.  Comparison of the activity of ionophores with other antibacterial agents against anaerobes.

Authors:  K Watanabe; J Watanabe; S Kuramitsu; H B Maruyama
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

Review 6.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

7.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

8.  Comparative study of penetration of lomefloxacin and ceftriaxone into transudative and exudative pleural effusion.

Authors:  M Kimura; T Matsushima; J Nakamura; Y Kobashi
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

9.  Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection.

Authors:  B C Lemaitre; D A Mazigh; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Ceftriaxone: in vitro studies and clinical evaluation.

Authors:  J W Gnann; W E Goetter; A M Elliott; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.